| 发明名称 |
EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM |
| 摘要 |
This invention relates to novel extended release pharmaceutical compositions of levetiracetam and preparations and characterizations thereof. This invention further relates to using these extended release pharmaceutical compositions of levetiracetam for the treatment of cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof. |
| 申请公布号 |
US2017105939(A1) |
申请公布日期 |
2017.04.20 |
| 申请号 |
US201615160424 |
申请日期 |
2016.05.20 |
| 申请人 |
AgeneBio, Inc. |
发明人 |
Gallagher Michela;Rosenzweig-Lipson Sharon;Melsopp Elsie;James Jack Lawrence |
| 分类号 |
A61K9/20;A61K9/00;A61K31/4015 |
主分类号 |
A61K9/20 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. An extended release pharmaceutical composition comprising:
a) 220 mg of levetiracetam; b) 280 mg-350 mg of hydroxypropyl methylcellulose; c) 1.2 mg-1.4 mg of colloidal silicon dioxide; d) 92.8 mg-119.2 mg of silicified microcrystalline cellulose;and
e) 6.0 mg-6.7 mg of magnesium stearate. |
| 地址 |
Baltimore MD US |
